Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a registered direct offering, a financing move that often pressures micro-cap biotech stocks due to dilution concerns.

Citius Prices Direct Offering At $5 Million

Citius Pharmaceuticals announced a registered direct offering for gross proceeds of $5 million priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company also noted the release is not an offer to sell or a solicitation to buy securities in any jurisdiction where such activity would be unlawful prior to registration or qualification under applicable securities laws.

The broader market is mixed today, with the Nasdaq up 1.1% and the Dow down 0.3% as market breadth stays slightly negative (advance/decline ratio of 0.8). CTXR's selloff is steeper than the Healthcare sector's -1.3% move, pointing to company-specific pressure on top of a weak sector session.

Citius Stock Remains In Repair Mode

CTXR is sitting near the lower end of its 52-week range ($2.48 high, 63 cents low), which keeps the longer-term chart in "repair mode" after repeated failed rebounds. The stock is trading 11.6% below its 20-day simple moving average (SMA) and 16.6% below its 100-day SMA, which suggests near-term sellers still control the trend even after prior bounces.

The moving average convergence divergence (MACD), a trend/momentum measure, is above its signal line with a positive histogram, which leans toward improving momentum versus the prior downswing. In everyday terms, MACD being above the signal line means downside pressure is easing, but it doesn't guarantee a sustained reversal.

The 50-day SMA remains below the 200-day SMA following the death cross in January, a longer-term bearish backdrop that can make rallies more likely to fade. Over the past 12 months, the stock is down 16.35%, which is consistent with a choppy-to-down longer-term tape where financing headlines can hit harder.

  • Key Resistance: $1.00 — a round-number area where rebounds often stall and supply can show up.
  • Key Support: 50 cents — a nearby "line in the sand" if selling pressure continues toward the prior low zone.

Citius Leans Into Oncology Therapies

Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with an emphasis on oncology, anti-infectives in adjunct cancer care, and distinct prescription products. The company's strategy targets unmet medical needs while aiming for lower development risk than typical new chemical entities.

Its flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, and the business operates as a single segment centered on targeted oncology therapies. In that context, a $5 million at-the-market registered direct offering matters because it can extend runway for development and commercialization plans, but it can also weigh on the stock near-term as investors reprice dilution risk.

Earnings And Analyst Outlook

Looking further out, the next major catalyst for the stock arrives with the May 13, 2026 (estimated) earnings report.

  • EPS Estimate: Loss of 32 cents (Up from $-1.27 YoY)
  • Revenue Estimate: $9.87 million (Up from $0.00 million YoY)
  • Valuation: P/E ratio not meaningful/available (common for development-stage biotech with losses)

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $6.00. Recent analyst moves include:

  • D. Boral Capital: Buy (Maintains Target to $6.00) (March 11)

Shares Slip On Friday

CTXR Stock Price Activity: Citius Pharmaceuticals shares were down 21.44% at $0.73 at the time of publication on Friday, according to Benzinga Pro data.

Read Also: What's Going On With Newmont Stock Friday? – Newmont (NYSE:NEM)

Image: Shutterstock